You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Approval to Covaxin premature, could be dangerous, says Shashi Tharoor

Senior Congress leader Shashi Tharoor on Sunday said that the emergency approval to Covid-19 vaccine--Covaxin is premature and could be dangerous as it is still under phase 3 trial

Topics
Shashi Tharoor | Coronavirus Vaccine | Health Ministry

ANI  |  General News 

Constitution and Upadhyay cannot go hand in hand, says Tharoor at JLF
Shashi Tharoor

Senior Congress leader on Sunday said that the emergency approval to COVID-19 vaccine--Covaxin is premature and could be dangerous as it is still under phase 3 trial. He urged Union Health Minister Dr Harsh Vardhan to wait till full trials of the vaccine are completed.

Taking to Twitter, Member of Parliament from Kerala's Thiruvananthapuram said, "The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous."

He further urged Union Health Minister Dr Harsh Vardhan to avoid Covaxin till full trials are over.

"Union Health Minister Dr Harsh Vardhan should please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime," he added in the tweet.

Earlier today, COVID-19 vaccines of Serum Institue of India and Bharat Biotech have been granted permission for restricted use in an emergency situation, said DCGI.

"After adequate examination, Central Drugs Standard Control Organisation(CDSCO) has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial," said VG Somani, DCGI, during a media briefing today.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, January 03 2021. 14:35 IST
RECOMMENDED FOR YOU